|
RU2693078C2
(ru)
|
2012-12-03 |
2019-07-01 |
Новиммун С.А. |
Анти-cd47 антитела и способы их применения
|
|
SG11201608393TA
(en)
|
2014-04-10 |
2016-11-29 |
Seattle Children S Hospital Dba Seattle Children S Res Inst |
Transgene genetic tags and methods of use
|
|
US11400115B2
(en)
|
2014-04-23 |
2022-08-02 |
Juno Therapeutics, Inc. |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
|
EP3143134B1
(en)
|
2014-05-15 |
2020-10-28 |
National University of Singapore |
Modified natural killer cells and uses thereof
|
|
KR101628872B1
(ko)
|
2014-05-28 |
2016-06-09 |
주식회사 레고켐 바이오사이언스 |
자가-희생 기를 포함하는 화합물
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
SG10202104804PA
(en)
|
2014-10-20 |
2021-06-29 |
Juno Therapeutics Inc |
Methods and compositions for dosing in adoptive cell therapy
|
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
|
US11458167B2
(en)
|
2015-08-07 |
2022-10-04 |
Seattle Children's Hospital |
Bispecific CAR T-cells for solid tumor targeting
|
|
CN108136038A
(zh)
|
2015-11-25 |
2018-06-08 |
乐高化学生物科学股份有限公司 |
包含肽基团的缀合物及其相关方法
|
|
RS65660B1
(sr)
|
2015-11-25 |
2024-07-31 |
Ligachem Biosciences Inc |
Konјugati koji sadrže samozapaljive grupe i postupci povezani sa njima
|
|
JP7327899B2
(ja)
|
2015-11-25 |
2023-08-16 |
レゴケム バイオサイエンシズ， インク． |
分岐リンカーを含む抗体－薬物複合体及びそれらに関連する方法
|
|
US12048718B2
(en)
|
2016-06-07 |
2024-07-30 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft |
Chimeric antigen receptor and CAR-T cells that bind BCMA
|
|
CN111848801B
(zh)
*
|
2016-09-06 |
2022-10-11 |
上海吉倍生物技术有限公司 |
一种抗cd19抗体及其制备方法和用途
|
|
US20180142018A1
(en)
*
|
2016-11-04 |
2018-05-24 |
Novimmune Sa |
Anti-cd19 antibodies and methods of use thereof
|
|
WO2018108106A1
(zh)
*
|
2016-12-13 |
2018-06-21 |
科济生物医药（上海）有限公司 |
抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
|
|
CN110248677B
(zh)
*
|
2017-01-05 |
2023-05-16 |
上海煦顼技术有限公司 |
人源化抗cd19抗体及其与嵌合抗原受体的用途
|
|
KR20240128814A
(ko)
|
2017-01-10 |
2024-08-27 |
프레시전 인코포레이티드 |
신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
|
|
JP7128829B2
(ja)
|
2017-02-17 |
2022-08-31 |
マップ バイオファーマシューティカル、インコーポレイテッド |
エボラ感染症の処置用のモノクローナル抗体およびカクテル
|
|
CA3053539A1
(en)
|
2017-02-27 |
2018-08-30 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
|
EP3595440A2
(en)
|
2017-03-14 |
2020-01-22 |
Juno Therapeutics, Inc. |
Methods for cryogenic storage
|
|
EP3601537A4
(en)
|
2017-03-27 |
2021-01-13 |
National University of Singapore |
STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
|
|
SG11201908492PA
(en)
|
2017-03-27 |
2019-10-30 |
Nat Univ Singapore |
Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
EP3604311A4
(en)
|
2017-03-29 |
2021-01-13 |
LegoChem Biosciences, Inc. |
PYRROLOBENZODIAZEPINE DIMERIC PRECURSOR AND ASSOCIATED LIGAND-BOND CONJUGATE COMPOUND
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
JOP20180042A1
(ar)
*
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
KR20200054160A
(ko)
|
2017-06-02 |
2020-05-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
|
|
AU2018281316B2
(en)
|
2017-06-07 |
2024-05-30 |
Precigen, Inc. |
Expression of novel cell tags
|
|
EP3441471A1
(en)
*
|
2017-08-08 |
2019-02-13 |
CEVEC Pharmaceuticals GmbH |
Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
|
|
KR20250096881A
(ko)
|
2017-08-09 |
2025-06-27 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포를 제조하기 위한 방법 및 조성물
|
|
CA3070579A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
|
US20210071258A1
(en)
|
2017-09-01 |
2021-03-11 |
Juno Therapeutics, Inc. |
Gene expression and assessment of risk of developing toxicity following cell therapy
|
|
US20200292526A1
(en)
|
2017-09-07 |
2020-09-17 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
|
WO2019055399A1
(en)
*
|
2017-09-12 |
2019-03-21 |
Igc Bio, Inc. |
ANTI-VEGF ANTIBODIES
|
|
CA3075915A1
(en)
|
2017-09-15 |
2019-03-21 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19 immunotherapy
|
|
JP7654240B2
(ja)
|
2017-09-19 |
2025-04-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
|
|
MA50185A
(fr)
|
2017-09-22 |
2020-07-29 |
Wuxi Biologics Ireland Ltd |
Nouveaux complexes polypeptidiques cd3/cd19 bispécifiques
|
|
KR20230007557A
(ko)
*
|
2017-09-22 |
2023-01-12 |
카이트 파마 인코포레이티드 |
키메라 폴리펩티드 및 그의 용도
|
|
MY202919A
(en)
|
2017-09-22 |
2024-05-29 |
Wuxi Biologics Ireland Ltd |
Novel bispecific polypeptide complexes
|
|
CN107759700A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd19抗原的转基因t细胞及其制备方法与应用
|
|
CN107759699A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd30抗原的转基因t细胞及其制备方法与应用
|
|
JP7258899B2
(ja)
|
2017-11-01 |
2023-04-17 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞組成物を作製するための方法
|
|
WO2019089855A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
KR20200076732A
(ko)
|
2017-11-03 |
2020-06-29 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Cd38-지시된 키메라 항원 수용체 작제물
|
|
CN118530373A
(zh)
|
2017-11-10 |
2024-08-23 |
朱拉生物公司 |
基于主要组织相容性复合物的嵌合受体和其用于治疗自身免疫性疾病的用途
|
|
WO2019109053A1
(en)
|
2017-12-01 |
2019-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
|
CA3083936C
(en)
*
|
2017-12-06 |
2022-08-23 |
Abclon Inc. |
Anti-cd19 antibody or antigen-binding fragment and cd19-specific chimeric antigen receptor comprising the same
|
|
SG11202005272SA
(en)
|
2017-12-08 |
2020-07-29 |
Juno Therapeutics Inc |
Process for producing a composition of engineered t cells
|
|
US12161670B2
(en)
|
2017-12-08 |
2024-12-10 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
|
KR102833956B1
(ko)
|
2017-12-08 |
2025-07-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포를 배양하기 위한 무혈청 배지 제형 및 이의 사용 방법
|
|
US10966999B2
(en)
|
2017-12-20 |
2021-04-06 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
JP7080514B2
(ja)
*
|
2017-12-22 |
2022-06-06 |
アブクロン・インコーポレイテッド |
悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
|
|
CN107903326B
(zh)
*
|
2018-01-02 |
2020-06-30 |
广东省人民医院(广东省医学科学院) |
包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物
|
|
CN108047332B
(zh)
*
|
2018-01-15 |
2021-08-24 |
阿思科力(苏州)生物科技有限公司 |
以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
EP3746117A1
(en)
|
2018-01-31 |
2020-12-09 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
CN111801348A
(zh)
|
2018-02-09 |
2020-10-20 |
新加坡国立大学 |
活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
|
|
JP7062792B2
(ja)
|
2018-02-13 |
2022-05-06 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｐｄ－１／ｐｄ－ｌ１阻害剤
|
|
WO2019178356A1
(en)
*
|
2018-03-14 |
2019-09-19 |
Dana-Farber Cancer Institute, Inc. |
Engineered cells, t cell immune modulating antibodies and methods for using the same
|
|
EA202091982A1
(ru)
*
|
2018-03-14 |
2021-06-10 |
Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) |
Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии
|
|
KR20200138741A
(ko)
|
2018-04-02 |
2020-12-10 |
내셔널 유니버시티 오브 싱가포르 |
면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
BR112020020887A2
(pt)
|
2018-04-12 |
2021-04-06 |
Umoja Biopharma, Inc |
Vetores virais e linhagens celulares de empacotamento
|
|
AR114789A1
(es)
*
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
EP3781556B1
(en)
|
2018-04-19 |
2025-06-18 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
US20210121466A1
(en)
|
2018-05-03 |
2021-04-29 |
Juno Therapeutics, Inc. |
Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
|
|
BR112020022299A2
(pt)
|
2018-05-09 |
2021-02-23 |
Legochem Biosciences, Inc. |
composições e métodos relacionados a conjugados de anticorpo-fármaco anti-cd19
|
|
KR102732008B1
(ko)
|
2018-05-14 |
2024-11-20 |
길리애드 사이언시즈, 인코포레이티드 |
Mcl-1 억제제
|
|
CN118221646A
(zh)
|
2018-07-13 |
2024-06-21 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
JP7560882B2
(ja)
|
2018-08-29 |
2024-10-03 |
ナショナル ユニヴァーシティー オブ シンガポール |
遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
|
|
AU2019346335B2
(en)
|
2018-09-28 |
2024-07-25 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
KR102635333B1
(ko)
|
2018-10-24 |
2024-02-15 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
MX2021005047A
(es)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences Inc |
Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
|
|
CN113227358A
(zh)
|
2018-10-31 |
2021-08-06 |
朱诺治疗学有限公司 |
选择并刺激细胞的方法及用于所述方法的设备
|
|
CN117105933A
(zh)
|
2018-10-31 |
2023-11-24 |
吉利德科学公司 |
具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
|
|
SG11202104183RA
(en)
|
2018-11-06 |
2021-05-28 |
Juno Therapeutics Inc |
Process for producing genetically engineered t cells
|
|
JP2022509017A
(ja)
*
|
2018-11-07 |
2022-01-20 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
抗ｐｔｋ７免疫細胞癌療法
|
|
CA3120118A1
(en)
|
2018-11-16 |
2020-05-22 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
|
IL283298B2
(en)
|
2018-11-30 |
2025-03-01 |
Juno Therapeutics Inc |
Methods for dosing and treating B-cell malignancies with adoptive cell therapy
|
|
WO2020113194A2
(en)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
|
CN111253487B
(zh)
*
|
2018-12-03 |
2024-02-02 |
广东东阳光药业股份有限公司 |
Cd19抗体及其应用
|
|
IL283734B2
(en)
|
2018-12-12 |
2025-03-01 |
Kite Pharma Inc |
Chimeric antigen receptors and CAR-T cells and methods of use
|
|
CN109734813B
(zh)
*
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
EP3912992A4
(en)
*
|
2019-02-04 |
2022-11-23 |
National University Corporation Ehime University |
Car library and production method for scfv
|
|
CN113874391B
(zh)
|
2019-02-20 |
2025-10-28 |
希望之城公司 |
靶向baff-r/cd19的嵌合抗原受体修饰的t细胞及其用途
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
|
|
AU2020231115B2
(en)
|
2019-03-07 |
2025-02-20 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
DK3934757T3
(da)
|
2019-03-07 |
2023-04-17 |
Inst Of Organic Chemistry And Biochemistry Ascr V V I |
2'3'-cykliske dinukleotider og prodrugs deraf
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
WO2020191336A1
(en)
|
2019-03-21 |
2020-09-24 |
Yamaguchi, Yukiko |
Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
KR20220016474A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 ｃｄ247 유전자 자리로부터 키메라 수용체를 발현하는 세포, 관련 폴리뉴클레오타이드 및 방법
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
MA56206A
(fr)
|
2019-06-12 |
2022-04-20 |
Juno Therapeutics Inc |
Combinaison thérapeutique d'une thérapie cytotoxique à médiation cellulaire et d'un inhibiteur d'une protéine de la famille bcl2 pro-survie
|
|
WO2020253879A1
(zh)
*
|
2019-06-21 |
2020-12-24 |
甘李药业股份有限公司 |
一种双特异性嵌合抗原受体
|
|
PE20220231A1
(es)
|
2019-06-25 |
2022-02-07 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
CN112210007B
(zh)
*
|
2019-07-11 |
2022-07-12 |
华夏英泰（北京）生物技术有限公司 |
一种cd19抗原高亲和力的抗体以及包含其cd19单链抗体区的嵌合抗原受体
|
|
WO2021016062A1
(en)
*
|
2019-07-19 |
2021-01-28 |
The Children's Hospital Of Philadelphia |
Chimeric antigen receptors containing glypican 2 binding domains
|
|
EP3769816A1
(en)
*
|
2019-07-25 |
2021-01-27 |
Ospedale Pediatrico Bambino Gesù |
Car-cd123 vector and uses thereof
|
|
JP2022545467A
(ja)
|
2019-08-22 |
2022-10-27 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
|
|
KR20210028544A
(ko)
|
2019-09-04 |
2021-03-12 |
주식회사 레고켐 바이오사이언스 |
인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
US11795223B2
(en)
|
2019-10-18 |
2023-10-24 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
KR20220101641A
(ko)
|
2019-10-30 |
2022-07-19 |
주노 테라퓨틱스 게엠베하 |
세포 선택 및/또는 자극 장치 및 사용 방법
|
|
US20240156863A1
(en)
*
|
2019-10-31 |
2024-05-16 |
Morphosys Ag |
Sequential anti-cd19 therapy
|
|
MX2022005123A
(es)
|
2019-10-31 |
2022-05-30 |
Forty Seven Inc |
Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
|
|
MX2022005524A
(es)
|
2019-11-07 |
2022-08-25 |
Juno Therapeutics Inc |
Combinacion de una terapia de celulas t y (s)-3-[4-(4-morfolin-4-i lmetil-benciloxi)-1-oxo-1,3-dihidro-isoindol-2-il]-piperidino-2,6 -diona.
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
AU2020395318A1
(en)
|
2019-12-06 |
2022-06-09 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating B cell malignancies
|
|
MX2022007930A
(es)
|
2019-12-24 |
2022-08-08 |
Carna Biosciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
MX2022008648A
(es)
|
2020-01-23 |
2022-12-15 |
The Children´S Medical Center Corp |
Diferenciacion de celulas t sin estroma a partir de celulas madre pluripotentes humanas.
|
|
MX2022009041A
(es)
|
2020-01-24 |
2022-10-07 |
Juno Therapeutics Inc |
Metodos de dosificacion y tratamiento de linfoma folicular y linfoma de zona marginal en terapia celular adoptiva.
|
|
KR20220146480A
(ko)
|
2020-01-28 |
2022-11-01 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｔ 세포 형질도입 방법
|
|
JP2023519098A
(ja)
|
2020-02-12 |
2023-05-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃｄ１９指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
|
|
BR112022014623A2
(pt)
|
2020-02-14 |
2022-09-13 |
Jounce Therapeutics Inc |
Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
|
|
JP2023517889A
(ja)
|
2020-03-10 |
2023-04-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
|
|
CA3173527A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
CN113402612A
(zh)
*
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US20240043427A1
(en)
|
2020-05-01 |
2024-02-08 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
EP4150057A2
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
JP7727662B2
(ja)
|
2020-05-13 |
2025-08-21 |
ジュノー セラピューティクス インコーポレイテッド |
臨床応答に関連する特徴量の特定方法およびその使用
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
TW202216776A
(zh)
|
2020-07-07 |
2022-05-01 |
美商康愈有限責任公司 |
Mic抗體及結合劑以及其使用方法
|
|
KR20230090367A
(ko)
|
2020-11-04 |
2023-06-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
|
|
US20230406922A1
(en)
|
2020-11-20 |
2023-12-21 |
Simcere Zaiming Pharmaceutical Co., Ltd. |
Humanized cd19 antibody and use thereof
|
|
WO2022115492A1
(en)
|
2020-11-24 |
2022-06-02 |
Lyell Immunopharma, Inc. |
Methods for making, compositions comprising, and methods of using rejuvenated t cells
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
EP4263600A1
(en)
|
2020-12-18 |
2023-10-25 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
TW202242117A
(zh)
|
2020-12-30 |
2022-11-01 |
美商亞勞諾斯醫療公司 |
包含多順反子表現卡匣之重組載體及其使用方法
|
|
WO2022150731A1
(en)
|
2021-01-11 |
2022-07-14 |
Sana Biotechnology, Inc. |
Use of cd8-targeted viral vectors
|
|
US20240108654A1
(en)
|
2021-03-03 |
2024-04-04 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
AU2022244229A1
(en)
|
2021-03-22 |
2023-09-14 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
|
CA3210581A1
(en)
|
2021-03-22 |
2022-09-29 |
Neil HAIG |
Methods of determining potency of a therapeutic cell composition
|
|
KR20240005700A
(ko)
|
2021-03-29 |
2024-01-12 |
주노 쎄러퓨티크스 인코퍼레이티드 |
체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법
|
|
WO2022212384A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7686086B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
EP4368640A4
(en)
*
|
2021-07-09 |
2025-01-22 |
Hainan Simcere Zaiming Pharmaceutical Co., Ltd. |
Cd19 antibody and application thereof
|
|
EP4370541A1
(en)
|
2021-07-14 |
2024-05-22 |
2seventy bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
|
TW202321457A
(zh)
|
2021-08-04 |
2023-06-01 |
美商薩那生物科技公司 |
靶向ｃｄ４之病毒載體之用途
|
|
WO2023015310A2
(en)
*
|
2021-08-06 |
2023-02-09 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
T-cell manufacturing methods
|
|
AR127745A1
(es)
*
|
2021-10-18 |
2024-02-28 |
Kite Pharma Inc |
Dominios de señalización para receptores quiméricos de antígenos
|
|
AU2022375782A1
(en)
|
2021-10-28 |
2024-05-02 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
EP4448549A2
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
|
US20250152709A1
(en)
|
2022-02-01 |
2025-05-15 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
JP2025509662A
(ja)
|
2022-03-24 |
2025-04-11 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｔｒｏｐ－２発現がんを治療するための併用療法
|
|
JP2025510415A
(ja)
*
|
2022-03-28 |
2025-04-14 |
ヴァイジェン－バイオ，インコーポレイテッド |
養子細胞療法用の遺伝的に操作された抗体抵抗性（ｇｅａｒ）細胞
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CN119546327A
(zh)
|
2022-04-08 |
2025-02-28 |
再生元制药公司 |
多部分受体和信号传导复合物
|
|
CN114716558B
(zh)
*
|
2022-04-12 |
2023-05-05 |
骏蓦(北京)生物科技有限公司 |
一种双特异性抗体及其治疗癌症的应用
|
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
AU2023272490A1
(en)
|
2022-05-17 |
2024-12-12 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
JP2025521543A
(ja)
|
2022-06-22 |
2025-07-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
|
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
CA3260083A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences Inc |
CD73 COMPOUNDS
|
|
JP2025531850A
(ja)
|
2022-09-08 |
2025-09-25 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
AU2023371640A1
(en)
|
2022-11-04 |
2025-05-15 |
Umoja Biopharma, Inc. |
Lentiviral particles displaying fusion molecules and uses thereof
|
|
TW202434735A
(zh)
|
2022-11-04 |
2024-09-01 |
美商烏莫賈生物製藥股份有限公司 |
展示黏著分子融合的顆粒
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
EP4633664A2
(en)
|
2022-12-13 |
2025-10-22 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
US20240254118A1
(en)
|
2022-12-22 |
2024-08-01 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
EP4658675A1
(en)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2024182516A1
(en)
|
2023-02-28 |
2024-09-06 |
Juno Therapeutics, Inc. |
Cell therapy for treating systemic autoimmune diseases
|
|
KR20250131823A
(ko)
|
2023-03-31 |
2025-09-03 |
아벨제타 인크. |
Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2024220588A1
(en)
|
2023-04-18 |
2024-10-24 |
Juno Therapeutics, Inc. |
Cytotoxicity assay for assessing potency of therapeutic cell compositions
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
CN121079300A
(zh)
|
2023-04-21 |
2025-12-05 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
WO2024226858A1
(en)
|
2023-04-26 |
2024-10-31 |
Juno Therapeutics, Inc. |
Methods for viral vector manufacturing
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
WO2025231174A1
(en)
|
2024-04-30 |
2025-11-06 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
WO2025235604A1
(en)
|
2024-05-08 |
2025-11-13 |
Umoja Biopharma, Inc. |
Fusion protein for use as immune cell engager
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|